Bengaluru, Karnataka, India: July 23, 2025: Biocon Biologics Limited (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Limited (BSE code: 532523, NSE: BIOCON), today announced the appointment of Deepali Naair as Global Head – Brand & Corporate Communications, effective immediately.
Deepali will lead the global brand and corporate communications function, responsible for defining and executing an integrated strategy that spans brand positioning, digital presence, regulatory and statutory communications, financial and corporate reporting, media relations, and employer branding.
With over three decades of experience across India, ASEAN, and Australia, Deepali brings deep expertise in brand building, marketing, and corporate reputation. In her most recent role as Group Chief Marketing Officer at CKA Birla Group, she was instrumental in shaping the Group’s corporate identity, launching new brands, and driving strategic transformations.
Deepali will join the Executive Leadership Team (ELT) and report directly to Shreehas Tambe, CEO & Managing Director, Biocon Biologics Limited. She will be based at Biocon House, Bengaluru.
Seema Ahuja, who was the Head of Communications for Emerging Markets and Corporate Brand, will post her retirement from Biocon Biologics move into a non-business facing role in Biocon Chairperson’s office to work on special projects. We thank Seema for her immense contribution to the company.
Shreehas Tambe, CEO & Managing Director, Biocon Biologics Limited, said: “Branding and communications play a pivotal role in shaping stakeholder perception, building trust, and translating corporate intent into meaningful narratives. As Biocon Biologics accelerates its journey to become a leading global biosimilars company, I am delighted to welcome Deepali and look forward to her leadership and expertise in shaping our global brand and communications strategy.”
About Biocon Biologics Limited:
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives. It is capitalizing on its ‘lab to market’ capabilities to serve over 5.8 million patients across 120+ countries by enabling affordable access to high quality biosimilars. The Company is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes.
Biocon Biologics has commercialized 10 biosimilars from its portfolio which are addressing the patients’ needs in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. It has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, bone health and other non-communicable diseases. The Company has many ‘firsts’ to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, it is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). Website: www.bioconbiologics.com; Follow us on X (formerly Twitter): @BioconBiologics and LinkedIn: Biocon Biologics for company updates.